An interventional study of Myofascial Release (MR) and clinical practice drug treatment in Headache, sponsored by Campus Bio-Medico University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Campus Bio-Medico University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Headache with a site in Italy — 7 open to participants now, 10 under way, 2 of them phase 3. Headache · Italy.
Among the 32 studies in Headache with a site in Italy, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2023, is one of 8 with no phase, and was the 21st registered.
764 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →7 of the 32 studies in Headache with a site in Italy are open now. Recruiting first, the newest first:
University of Florence · Sites in Italy
Ages 18+
University of Florence · Sites in Italy
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, United States, Argentina and 10 more countries
Ages 18+
University of Florence · Sites in Italy
Ages 18+
IRCCS National Neurological Institute "C. Mondino" Foundation · Sites in Italy
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 65 across 562 interventional studies indexed under Headache.
Median enrollment 298 across the 20 interventional studies, 100 across the 12 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 32 have an industry lead sponsor. The 10 most frequent:
Campus Bio-Medico University is the lead sponsor of 84 studies on the registry; 11 are open to participants now.
Campus Bio-Medico University has 1 study filed under Headache — fewer than ten, so there is no comparison to draw.
1 of the studies in Headache with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06409832University of FlorenceRimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Headache with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to evaluate which is the best approach for the non-pharmacological treatment of patients with different types of primary headaches (tension-type headache (TTC), trigeminal autonomic headache (TACs) and migraine) or cervicogenic headache by comparing three methods of intervention to control treatment (drug therapy): therapeutic exercise (TE), myofascial release + TE, and Mulligan's manual therapy + TE. The efficacy will be evaluated in terms of reduction of headache episodes, pain intensity and its duration.
Patients will be evaluated before the start of treatment (T0), at the end of treatment (T1), 3 months after T1 (T2), 6 months after T1 (T3). Results will be stratified by gender, age range, and type of headache diagnosed.
The 3 non-pharmacological treatment groups will carry out 12 treatment sessions, 3 times a week for 4 weeks, with a duration of 45 minutes each. The control group (CTRL) will carry out pharmacological treatment according to clinical practice, the patients of the CTRL group at the end of the last follow-up evaluation (T3 at 6 months) at their request will be randomized into one of the other three intervention groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the MR+TE group will undergo 12 sessions (3 d/week) of sub-occipital inhibition treatment as a combined muscle and soft tissue inhibition technique. The physiotherapist will apply deep pressure which will be maintained for a total of 10 minutes until the sub-occipital tissues are released. In addition to this technique, the method of pumping and manual treatment (acupressure) of the trigger points on the sub-occipital muscles, on the upper bundles of the trapezius bilaterally, on the sternocleidomastoid bilaterally and on the scalene muscles bilaterally will be applied for a further 10 minutes for a total treatment with myofascial release equal to 20 minutes. At the end of the MR session, the 20-minute TE session will be performed in the same way as described in the TE intervention group.
Other: Myofascial Release (MR) · Other: Therapeutic exercise (TE)
The MT+TE intervention group will carry out rehabilitation treatment with a structured protocol based on mobilizations according to the Mulligan method. Treatment according to Mulligan will be carried out at the discretion of the therapist on the basis of daily evaluations of cervical dysfunction and the eventual manifestation of headache. 5 different techniques will be performed on the patient in 12 sessions (3 v/week, for 4 weeks) as described in Satpute, K., Bedekar, N. \& Hall, T. Effectiveness of Mulligan manual therapy over exercise on headache frequency, intensity and disability for patients with migraine, tension-type headache and cervicogenic headache - a protocol of a pragmatic randomized controlled trial. BMC Musculoskelet Disord 22, (2021)..
Other: Manual therapy (MT) · Other: Therapeutic exercise (TE)
Patients in the TE intervention group will be asked to perform 12 sessions (3 day/week) of TE supervised by a physiotherapist. Each session will have a total duration of 40 min divided into 20 min of aerobic exercise and 20 min of TE. Aerobic exercise consists of a total of 20 min of activity on a stationary bike using parameters to increase performance (intensity over 20 min) progressively based on fatigue (Borg scale).The TE consists of warm-up and cool-down exercises for the cervical ROM, associated with stretching exercises of the cervical and scapulothoracic muscles. After the warm-up, muscle strengthening exercises will be performed (isometric, concentric and eccentric contractions of the cervical muscles).
Other: Therapeutic exercise (TE)
Patients assigned to the control group will follow the pharmacological treatment according to medical doctor indications (clinical practice).
Drug: clinical practice drug treatment
Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.
drug treatment according to the medical indications of clinical practice
The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
Also known as: Mulligan Concept
The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).
Headache frequency
number of headache attacks in one month
Time frame: 4 weeks (end of treatment)
Headache frequency
number of headache attacks in one month
Time frame: 3 months after the end of the treatment
Headache frequency
number of headache attacks in one month
Time frame: 6 months after the end of the treatment
Headache clinical presentation
the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)
Time frame: 4 weeks (end of treatment)
Headache clinical presentation
the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)
Time frame: 3 months after the end of the treatment
Headache clinical presentation
the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)
Time frame: 6 months after the end of the treatment
Headache related disability
The headache related disability is assessed through the neck disability index
Time frame: 4 weeks (end of treatment)
Headache related Disability
The headache related disability is assessed through the neck disability index
Time frame: 3 months after the end of the treatment
Headache related Disability
The headache related disability is assessed through the neck disability index
Time frame: 6 months after the end of the treatment
Headache related Disability
The headache related disability is assessed through the migraine disability assessment test.
Time frame: 4 weeks (end of treatment)
Headache related Disability
The headache related disability is assessed through the migraine disability assessment test.
Time frame: 3 months after the end of the treatment;
Headache related Disability
The headache related disability is assessed through the migraine disability assessment test.
Time frame: 6 months after the end of the treatment
Perceived Quality of life
The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)
Time frame: 4 weeks (end of treatment)
Perceived Quality of life
The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)
Time frame: 3 months after the end of the treatment
Perceived Quality of life
The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)
Time frame: 6 months after the end of the treatment
Perceived Quality of life
The quality of life is assessed through the Short Form-36 Health Survey
Time frame: 4 weeks (end of treatment)
Perceived Quality of life
The quality of life is assessed through the Short Form-36 Health Survey
Time frame: 3 months after the end of the treatment
Perceived Quality of life
The quality of life is assessed through the Short Form-36 Health Survey
Time frame: 6 months after the end of the treatment
Cervical Range of Motion
Active cervical range of motion recorded through the dynamo vald system
Time frame: 4 weeks (end of treatment)
Cervical Range of Motion
Active cervical range of motion recorded through the dynamo vald system
Time frame: 3 months after the end of the treatment
Cervical Range of Motion
Active cervical range of motion recorded through the dynamo vald system
Time frame: 6 months after the end of the treatment
Cervical muscles Strength
Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)
Time frame: 4 weeks (end of treatment)
Cervical muscles Strength
Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)
Time frame: 3 months after the end of the treatment
Cervical muscles Strength
Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)
Time frame: 6 months after the end of the treatment
Drug intake
Number of drug intake reported in the headache diary
Time frame: 4 weeks (end of treatment)
Drug intake
Number of drug intake reported in the headache diary
Time frame: 3 months after the end of the treatment
Drug intake
Number of drug intake reported in the headache diary
Time frame: 6 months after the end of the treatment
Started Apr 2023 (actual). Primary completion is estimated for Feb 2025, 22 months after the start.
Of 177 non-industry interventional studies with no phase under Headache, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 22 months is above that.
Counting every sponsor, half of 196 studies reached it within 14 months; a quarter within 6 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Campus Bio-Medico University